EU focuses on safety and effectiveness of pandemic vaccines
This article was originally published in Scrip
As vaccination campaigns against pandemic flu get underway, the European regulatory and health authorities have laid out their strategy for monitoring the benefit-risk profiles of the various vaccines. The emphasis will be on the rapid detection and reporting of major safety issues such as life-threatening reactions and birth defects, as well as on the effectiveness and immunogenicity of the individual vaccines.
You may also be interested in...
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.